A trial directly comparing two commonly used blood-thinning drugs found that one carries a lower risk of dangerous bleeding ...
March 13 (Reuters) - A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - found that Eliquis carries a clearly lower risk of ...
In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
THIRD APPROVAL: Regulators in Japan have approved anticlotting drug called Eliquis, a potential blockbuster from Bristol-Myers Squibb and Pfizer. It’s already on sale in Canada and the European Union.
By Jody Godoy PHILADELPHIA, March 17 (Reuters) - The U.S. Federal Trade Commission is on the lookout for anticompetitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results